Literature DB >> 3873953

Effects of recombinant leukocyte interferon (rIFN-alpha A) on tumour growth and immune responses in patients with metastatic melanoma.

P Hersey, E Hasic, M MacDonald, A Edwards, A Spurling, A S Coates, G W Milton, W H McCarthy.   

Abstract

Studies were initiated to assess the response of patients with disseminated melanoma to recombinant alpha interferon (rIFN-alpha A) and to monitor effects of rIFN-alpha A on several tests of immune function. Twenty patients were treated with rIFN-alpha A given by i.m. injection in escalating doses from 15 to 50 X 10(6) um-2. The responses of two patients were considered unevaluable. Of the remainder there was complete remission of tumour in two and stable disease in two. Subsequent progression of tumour in one of the latter patients coincided with development of antibodies to IFN. Side effects (usually fatigue) were dose rate limiting in 11 patients. Laboratory tests on samples taken 6 hours after rIFN-alpha A indicated a marked lymphopenia and a reduction in natural killer (NK) cell activity particularly against K562 target cells. Longer term changes measured in samples taken 2 days after the previous rIFN-alpha A injections consisted of neutropenia and an increase in the T4/T8 ratio due mainly to a relative increase in OKT4 positive T cells compared to OKT8 positive T cells. NK activity against the K562 target cell increased in most patients during the first week of treatment and then returned to below or near pretreatment levels thereafter against the K562 target cell. This contrasted with NK activity against the melanoma target cell which showed a more gradual increase over the duration of the treatment in 6 patients. The latter correlated with an increase in mitogen stimulated IL 2 production from their blood lymphocytes and may indicate that the cytotoxic activity resulted from lymphokine-activated killer (LAK) cells. These results confirm the activity of rIFN-alpha A against melanoma in certain patients. They suggest that further studies are needed to select patients who may respond to rIFN-alpha A and to optimize treatment regimens. Tests of IL 2 production and LAK activity may assisted in achieving these objectives.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3873953      PMCID: PMC1977086          DOI: 10.1038/bjc.1985.127

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  21 in total

1.  Disappearance of the NK effect after explantation of lymphocytes and generation of similar nonspecific cytotoxicity correlated to the level of blastogenesis in activated cultures.

Authors:  M G Masucci; E Klein; S Argov
Journal:  J Immunol       Date:  1980-05       Impact factor: 5.422

2.  The effects of prednisolone in leucocyte function in man. A double blind controlled study.

Authors:  J R Clarke; R F Gagnon; F M Gotch; M R Heyworth; I C Maclennan; S C Truelove; C A Waller
Journal:  Clin Exp Immunol       Date:  1977-05       Impact factor: 4.330

3.  Reporting results of cancer treatment.

Authors:  A B Miller; B Hoogstraten; M Staquet; A Winkler
Journal:  Cancer       Date:  1981-01-01       Impact factor: 6.860

4.  Induction of cytotoxic activity in human lymphocytes against autologous and allogeneic melanoma cells in vitro by culture with interleukin 2.

Authors:  P Hersey; C Bindon; A Edwards; E Murray; G Phillips; W H McCarthy
Journal:  Int J Cancer       Date:  1981-12       Impact factor: 7.396

5.  Lymphokine production by PHA-stimulated human lymphocytes is enhanced by interferon.

Authors:  H Blomgren; S Einhorn
Journal:  Int Arch Allergy Appl Immunol       Date:  1981

6.  Human leukocyte (alpha) interferon in metastatic malignant melanoma: the American Cancer Society phase II trial.

Authors:  S E Krown; M W Burk; J M Kirkwood; D Kerr; D L Morton; H F Oettgen
Journal:  Cancer Treat Rep       Date:  1984-05

7.  Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients.

Authors:  J U Gutterman; S Fine; J Quesada; S J Horning; J F Levine; R Alexanian; L Bernhardt; M Kramer; H Spiegel; W Colburn; P Trown; T Merigan; Z Dziewanowski
Journal:  Ann Intern Med       Date:  1982-05       Impact factor: 25.391

8.  Systemic administration of human leukocyte interferon to melanoma patients. I. Effects on natural killer function and cell population.

Authors:  S H Golub; F Dorey; D Hara; D L Morton; M W Burk
Journal:  J Natl Cancer Inst       Date:  1982-05       Impact factor: 13.506

9.  Role of G0-G1 arrest in the inhibition of tumor cell growth by interferon.

Authors:  A A Creasey; J C Bartholomew; T C Merigan
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

10.  Tumour-related changes in natural killer cell activity in melanoma patients. Influence of stage of disease, tumour thickness and age of patients.

Authors:  P Hersey; A Edwards; W H McCarthy
Journal:  Int J Cancer       Date:  1980-02-15       Impact factor: 7.396

View more
  16 in total

1.  IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC.

Authors:  Gordana Konjević; Viktor Jović; Vladimir Jurisić; Sinisa Radulović; Svetislav Jelić; Ivan Spuzić
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

2.  Effects of recombinant leukocyte interferon on serum immunoglobulin concentrations and lymphocyte subpopulations in chronic hepatitis B.

Authors:  H Tsuji; K Murai; K Akagi; M Fujishima
Journal:  J Clin Immunol       Date:  1990-01       Impact factor: 8.317

Review 3.  Lymphocyte subsets as prognostic markers for cancer patients receiving immunomodulative therapy.

Authors:  M Hernberg
Journal:  Med Oncol       Date:  1999-09       Impact factor: 3.064

Review 4.  Interferon-alpha in malignant and viral diseases. A review.

Authors:  R T Dorr
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

Review 5.  The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.

Authors:  Lana E Kandalaft; Nathan Singh; John B Liao; Andrea Facciabene; Jonathan S Berek; Daniel J Powell; George Coukos
Journal:  Gynecol Oncol       Date:  2009-12-02       Impact factor: 5.482

6.  A phase II study of combined administration of dacarbazine and carboplatin with home therapy of recombinant interleukin-2 and interferon-alpha 2a in patients with advanced malignant melanoma.

Authors:  I G Ron; Y Mordish; A Eisenthal; Y Skornick; M J Inbar; S Chaitchik
Journal:  Cancer Immunol Immunother       Date:  1994-06       Impact factor: 6.968

7.  Cytokine production in whole blood cell cultures of patients undergoing therapy with biological response modifiers or 5-fluorouracil.

Authors:  U Elsässer-Beile; S von Kleist; A Lindenthal; R Birken; H Gallati; J S Mönting
Journal:  Cancer Immunol Immunother       Date:  1993-08       Impact factor: 6.968

8.  Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma.

Authors:  C I Falkson
Journal:  Med Oncol       Date:  1995-03       Impact factor: 3.064

9.  Potentiation of interleukin-2 production and its binding by monoclonal antibodies to the gangliosides GD3 and GD2.

Authors:  S Schibeci; P Hersey; D Cheresh
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

10.  Recombinant interferon alpha-2a in combination with dacarbazine in the treatment of metastatic malignant melanoma: analysis of long-term responding patients.

Authors:  I G Ron; M J Inbar; M Gutman; O Merimsky; S Chaitchik
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.